PSYCHOSOCIAL FACTORS IN SUDDEN CARDIAC DEATH

《突发心脏事件的心理社会因素结局研究》 死亡(全氟辛烷磺酸)“是一个独立的项目，是对正在进行的 NIH临床试验“心源性猝死心力衰竭试验(SCD-HeFT)”。这个 全氟辛烷磺酸研究将1)评估心理社会(心理学：焦虑、抑郁； 社会：300名患者的社会支持、宠物饲养、生活压力)状况 在基线、一个月后和每隔一个月登记参加SCD-HeFT临床试验 6个月，为期2年；2)调查 影响心脏病患者生存的社会心理因素；3) 评价植入型心律转复除颤器(ICD)对心脏功能的影响 以ICD为主要治疗手段的心力衰竭患者的心理社会状况 预防心源性猝死(SCD)；以及4)比较心理社会 ICD的影响与其他HF治疗的影响。SCD-Heft，初级 预防试验，旨在比较三种随机试验的效果 改善心力衰竭患者生存的指定治疗。三位一体 治疗方法有：常规治疗心力衰竭和安慰剂，常规治疗心力衰竭 心衰和胺碘酮，以及心衰和ICD的常规治疗。全氟辛烷磺酸将利用 SCD-HeFT生理和人口学数据。具体的假设将得到检验。 最小乘方为0.8，采用Logistic多元回归，线性倍数 回归分析、卡方检验和多元方差分析。心力衰竭 在美国影响到100-200万人。因心肌梗死而死亡 由于治疗方法的改善，脑梗塞已经减少，生活在 患心力衰竭的人数有所增加。超过一半的死于心力衰竭是由于SCD。这个 全氟辛烷磺酸的结果有可能影响护理实践，挽救生命 减少心力衰竭患者的风险，并防止随着心力衰竭的进展而增加医疗费用。护理 在管理心脏病患者和他们的治疗方面起着重要的治疗作用 家人。必须有针对性地采取干预措施，以最大限度地提高 降低死亡率和发病率。全氟辛烷磺酸将确定高风险概况 适用于心力衰竭患者。使用此配置文件，护士可以最大限度地识别患者 风险和制定干预措施，以改变心理社会痛苦的形式， 这特别会导致SCD和长期的心理社会痛苦。这个 结合全氟辛烷磺酸和SCD-HeFT的数据将提供全面评估 心力衰竭患者。

This proposal "Psychosocial Factor Outcome Study in Sudden Cardiac Death (PFOS)" constitutes an independent project complimentary to the ongoing NIH clinical trial, "Sudden Cardiac Death Heart Failure Trial (SCD-HeFT)." The PFOS study will 1) assess psychosocial (Psychological: anxiety, depression; social: social support, pet ownership, life stress) status of 300 patients enrolled in the SCD-HeFT clinical trial at baseline, after one month, and every six months for 2 years; 2) investigate the independent contributions of baseline psychosocial factors to survival of heart patients (HF) patients; 3) evaluate the impact of implanted cardioverter defibrillators (ICD) on the psychosocial status of heart failure (HF) patients who receive ICD as primary prevention for sudden cardiac death (SCD); and 4) compare the psychosocial impact of ICD with the impact of the other HF treatments. The SCD-HeFT, primary prevention trial, is designed to compare the effectiveness of three randomly assigned treatments in improving survival for patients with HF. The three treatments are: conventional therapy of HF and placebo, conventional therapy of HF and Amiodarone, and conventional therapy of HF and ICD. PFOS will utilize SCD-HeFT physiological and demographic data. Specific hypotheses will be tested with a minimum power of .8, using logistic multiple regression, linear multiple regression, chi-square, and multivariate analysis of variance. Heart failure affects 1-2 million people in the United States. As mortality from myocardial infarction has decreased due to improved treatment, the number of people living with HF has increased. Over half of the deaths from HF are due to SCD. The results of the PFOS have potential to influence nursing practice, save lives of HF patients, and prevent escalated health care costs as HF progresses. Nursing plays a major therapeutic role in the management of cardiac patients and their families. It is imperative to target interventions to maximize effectiveness at decreasing mortality and morbidity. The PFOS will identify a high-risk profile for HF patients. Using this profile, nurses can identify patients at greatest risk and develop interventions to modify the forms of psychosocial distress, which specifically contribute to SCD and long term psychosocial distress. The combination of data from PFOS and SCD-HeFT will provide a holistic assessment of HF patients.